Fulgent Genetics

Fulgent Genetics operates one of the most comprehensive genetic testing platforms in the U.S., offering over 18,000 single gene tests and 900+ rare disease panels. The company has expanded into therapeutic development with a focus on novel cancer therapies using nanoencapsulation technology. It recently launched new prenatal screening products and secured major contracts such as a five-year agreement with the U.S. Department of Veterans Affairs to provide hereditary cancer and pharmacogenetic testing. Clinical results from its diagnostic business are robust due to high test volume but specific clinical trial data on therapeutics are not publicly detailed.